about
Severe and persistent depletion of circulating plasmacytoid dendritic cells in patients with 2009 pandemic H1N1 infection.In vivo release of alpha-defensins in plasma, neutrophils and CD8 T-lymphocytes of patients with HIV infection.In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response.Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced diseaseParamyosin of Echinococcus granulosus: cDNA sequence and characterization of a tegumental antigen.Invasive aspergillosis in patients with liver disease.Chlamydia pneumoniae seroprevalence among HIV-1-infected and uninfected people with known HIV risk factor.Candidal thrombophlebitis of central veins: case report and review.Mutational resistance pattern of HIV type 1 in CD14+ monocytes, CD4+ T cells, and plasma from treated patients.A seven-year prospective study on spondylodiscitis: epidemiological and microbiological features.Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy.The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir.Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis.Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients.Interleukin-15 modulates interferon-gamma and beta-chemokine production in patients with HIV infection: implications for immune-based therapy.Plasmacytoid dendritic cells count in antiretroviral-treated patients is predictive of HIV load control independent of CD4+ T-cell count.Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response.Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection.Ex vivo and in vitro effect of human immunodeficiency virus protease inhibitors on neutrophil apoptosis.Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients.Primary retroperitoneal abscesses due to Rhodococcus equi in a patient with severe nephrotic syndrome: successful antibiotic treatment with linezolid and tigecycline.QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of Mycobacterium tuberculosis infection in a cohort of patients enrolled with suspected tuberculosis.Immunoblot analysis of Salmonella typhi lipopolysaccharide (LPS) using typhoid sera.Tumour Necrosis Factor-alpha Production and Immune Cell Activation in Tuberculous MeningitisInterferon-γ release assay in HIV-infected patients with active tuberculosis: impact of antituberculous drugs on host immune response.Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc.Detection of mycobacterial antigen by dot blot assay in the cerebrospinal fluid of patients with tuberculous meningitis.Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.Atypical localization of Leishmaniasis in an intestinal polyp.Overexpression of monosialoganglioside GM3 on lymphocyte plasma membrane in patients with HIV infection.In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.Human immunodeficiency virus-1 specific and natural cellular immunity in HIV seronegative subjects with multiple sexual exposures to virus.Influence of previous tuberculin skin test on serial IFN-γ release assays.Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.The role of IL-15 in challenging Acquired Immunodeficiency SyndromeSuccessful conservative treatment of peripheral candidal thrombophlebitis: case reportIncreased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatmentTuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-α (anti-TNF-α) treatment
P50
Q30403278-21E0877F-08C2-4FD7-809E-E377EFE8F094Q30904461-33275A6C-4F4E-4C62-B0DC-E8CFBE752D8AQ33429956-16667E63-DD1C-4B5C-BB39-0EFFC1C67F62Q33999316-FC622128-2AAD-4B95-B944-3A7236926B96Q34100037-71DF8378-8F46-4234-9223-596C1AA8ABE2Q36761475-5043EC60-3512-4910-AB6D-AE04D2DD4A87Q37812386-5A70D20C-82CD-46F8-91E8-0A2CEAEFF8C5Q37884226-FB095F83-90BC-4578-904F-DBE1131F29D5Q37929789-06A39607-C306-46A3-8BFA-14A59CA745FCQ38416368-9A8E6AE5-4098-4268-96C0-2732682CF178Q38958999-A8D64A33-795D-43F4-9A9F-FCC8C5463C14Q38959246-5738314D-0923-48AD-B514-01F642FF1C2BQ38959260-48342AAC-99DD-4BC8-A18C-7DAD644348C4Q38959269-1BD0985A-6CEF-47C3-848A-A304633C940EQ38959278-09AB6805-2CFC-4D69-B69F-028181ADDBDBQ38959293-568DD452-A5B9-40B7-A52D-5662061AF713Q39008104-2D8B4242-8760-41EB-9EC2-64E371BFFA89Q39178910-D3BCB714-7047-4663-BAA0-24799003C86BQ39178924-82AC8C77-F979-4412-AB76-7304C79E942AQ39223327-81332782-E078-449E-9B3A-A8C7A39A015CQ39223332-F032E89D-809C-4A80-928B-7D4DC6DBF468Q39223341-5FD4B36B-624F-4473-BE70-47FCDA278E8CQ39414895-D295038C-5103-4EFA-9096-A0938440918CQ39433473-2FADE583-E88F-4E19-BD30-CB4E29BCDDEAQ40802584-093B61C0-1656-4F6A-B208-B8ECFDAA7589Q42123865-A230EB93-A852-47FC-82F9-E933E717B035Q42213894-6380199C-013E-4EFA-8E48-7A2D1108E1BCQ42963370-1CD0D938-B6D2-4C79-A9E5-D000B215EC03Q43909162-66B9FEDA-C2C0-426D-A1F5-2214A8FE995BQ44188591-8D16FF85-B9E3-4C7A-BD99-DB50CAD4BB7EQ44362455-E5116F8F-C84E-4B75-A5C6-E4C0DF0F256FQ44777288-9994FBED-DD81-42AD-ABA0-98B52950772AQ45362666-7270B64D-3849-4415-8C17-815F35ACE75BQ45736750-38CE3FCF-A323-4888-A4CB-68E2A4A5511BQ45886145-EAF2FBF8-3204-41B2-B18E-6D37ADEA689CQ46699455-6F4ADCA8-2458-4ACF-A911-2879DF5FADEFQ57573960-9A8CB913-DDC7-4C8D-8DF2-A40019C34CBCQ58480090-4BEADB2B-140D-474D-B4EE-DE3301D8618AQ58480094-66DDB325-CB68-4C43-925B-907DE77370FCQ58480098-AE88A52A-516D-4DE5-B729-F2B37F9AEE0F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anna Paola Massetti
@ast
Anna Paola Massetti
@en
Anna Paola Massetti
@es
Anna Paola Massetti
@nl
Anna Paola Massetti
@sl
type
label
Anna Paola Massetti
@ast
Anna Paola Massetti
@en
Anna Paola Massetti
@es
Anna Paola Massetti
@nl
Anna Paola Massetti
@sl
altLabel
paola massetti
@en
prefLabel
Anna Paola Massetti
@ast
Anna Paola Massetti
@en
Anna Paola Massetti
@es
Anna Paola Massetti
@nl
Anna Paola Massetti
@sl
P106
P21
P31
P496
0000-0003-0520-8743